149 related articles for article (PubMed ID: 33258154)
21. Malignant biphasic peritoneal mesothelioma in a child: fine-needle aspiration cytology, histopathology, and immunohistochemical features along with review of literature.
Arora SK; Srinivasan R; Nijhawan R; Bansal D; Menon P
Diagn Cytopathol; 2012 Dec; 40(12):1112-5. PubMed ID: 21574263
[TBL] [Abstract][Full Text] [Related]
22. Malignant pleural mesothelioma metastatic to the submandibular salivary gland, simulating glandular hypertrophy, diagnosed by fine-needle aspiration biopsy: a case report and literature review.
Ambroggi M; Orlandi E; Foroni RP; Cavanna L
World J Surg Oncol; 2014 Apr; 12():129. PubMed ID: 24773769
[TBL] [Abstract][Full Text] [Related]
23. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
Forest F; Patoir A; Dal Col P; Sulaiman A; Camy F; Laville D; Bayle-Bleuez S; Fournel P; Habougit C
Pathology; 2018 Oct; 50(6):635-641. PubMed ID: 30145072
[TBL] [Abstract][Full Text] [Related]
24. An immunohistochemical comparison of two TTF-1 monoclonal antibodies in atypical squamous lesions and sarcomatoid carcinoma of the lung, and pleural malignant mesothelioma.
Klebe S; Swalling A; Jonavicius L; Henderson DW
J Clin Pathol; 2016 Feb; 69(2):136-41. PubMed ID: 26281863
[TBL] [Abstract][Full Text] [Related]
25. Aberrant Cytokeratin 20 Reactivity in Epithelioid Malignant Mesothelioma: A Case Report.
Manur R; Lamzabi I
Appl Immunohistochem Mol Morphol; 2019; 27(10):e93-e96. PubMed ID: 28248731
[TBL] [Abstract][Full Text] [Related]
26. Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma.
Creaney J; Dick IM; Meniawy TM; Leong SL; Leon JS; Demelker Y; Segal A; Musk AW; Lee YC; Skates SJ; Nowak AK; Robinson BW
Thorax; 2014 Oct; 69(10):895-902. PubMed ID: 25037982
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma.
Inaguma S; Wang Z; Lasota J; Onda M; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; Okoń K; Biernat W; Ikeda H; Schrump DS; Hassan R; Pastan I; Miettinen M
Oncotarget; 2017 Apr; 8(16):26744-26754. PubMed ID: 28460459
[TBL] [Abstract][Full Text] [Related]
28. The recurrence of malignant pleural mesothelioma 14 years after extrapleural pneumonectomy: possible histological transformation.
Kinoshita T; Ishii G; Matsumura Y; Shiozawa T; Aokage K; Hishida T; Yoshida J; Nagai K
Pathol Int; 2012 Nov; 62(11):754-7. PubMed ID: 23121607
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis.
Tian L; Zeng R; Wang X; Shen C; Lai Y; Wang M; Che G
Oncotarget; 2017 Jul; 8(28):46425-46435. PubMed ID: 28507279
[TBL] [Abstract][Full Text] [Related]
30. Epithelioid pleural mesothelioma concurrently associated with miliary pulmonary metastases and minimal change nephrotic syndrome - A hitherto undescribed case.
Tsukamoto Y; Otsuki T; Hao H; Kuribayashi K; Nakano T; Kida A; Nakanishi T; Funatsu E; Noguchi C; Yoshihara S; Kaku K; Hirota S
Pathol Res Pract; 2015 Dec; 211(12):1014-9. PubMed ID: 26376466
[TBL] [Abstract][Full Text] [Related]
31. Malignant mesothelioma metastatic to the skin, presenting as inflammatory carcinoma.
Prieto VG; Kenet BJ; Varghese M
Am J Dermatopathol; 1997 Jun; 19(3):261-5. PubMed ID: 9185913
[TBL] [Abstract][Full Text] [Related]
32. Histopathologic features predict survival in diffuse pleural malignant mesothelioma on pleural biopsies.
Habougit C; Trombert-Paviot B; Karpathiou G; Casteillo F; Bayle-Bleuez S; Fournel P; Vergnon JM; Tiffet O; Péoc'h M; Forest F
Virchows Arch; 2017 Jun; 470(6):639-646. PubMed ID: 28349237
[TBL] [Abstract][Full Text] [Related]
33. Pleural mesothelioma: diagnostic problems and evaluation of prognostic factors.
Ismail HM; Nouh MA; Abulkheir IL; Abd El-Rahman Ael-R; Tawfik HN
J Egypt Natl Canc Inst; 2006 Dec; 18(4):303-10. PubMed ID: 18301454
[TBL] [Abstract][Full Text] [Related]
34. High mesothelin expression by immunohistochemistry predicts improved survival in pleural mesothelioma.
Chu GJ; Linton A; Kao S; Klebe S; Adelstein S; Yeo D; Rasko JEJ; Cooper WA
Histopathology; 2023 Aug; 83(2):202-210. PubMed ID: 37040900
[TBL] [Abstract][Full Text] [Related]
35. Malignant pleural mesothelioma with lacrimal gland metastasis.
Hanafi H; Verdijk RM; Paridaens D
Acta Ophthalmol; 2016 Dec; 94(8):836-838. PubMed ID: 27422678
[TBL] [Abstract][Full Text] [Related]
36. Metastases to the oral region from pleural mesothelioma: Clinicopathologic review.
Sinon SH; Rich AM; Hussaini HM; Yoon HS; Firth NA; Seymour GJ
Head Neck; 2013 Apr; 35(4):599-604. PubMed ID: 22083802
[TBL] [Abstract][Full Text] [Related]
37. Subcutaneous metastases of sarcomatoid mesothelioma with its differential diagnosis on fine needle aspiration--a case report.
Patel T; Bansal R; Trivedi P; Modi L; Shah MJ
Indian J Pathol Microbiol; 2005 Oct; 48(4):482-4. PubMed ID: 16366102
[TBL] [Abstract][Full Text] [Related]
38. Skin metastasis of pleural epithelioid malignant mesothelioma.
Terada T
Appl Immunohistochem Mol Morphol; 2011 Jan; 19(1):92-3. PubMed ID: 20861794
[No Abstract] [Full Text] [Related]
39. Immunohistochemical diagnosis of epithelioid mesothelioma: an update.
Ordóñez NG
Arch Pathol Lab Med; 2005 Nov; 129(11):1407-14. PubMed ID: 16253021
[TBL] [Abstract][Full Text] [Related]
40. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
